Combining Matrx’s SĀPH™ with an active peptide from vascular endothelial growth factor (VEGF), Matrx has selected the novel, combined molecule MTX61 as its lead compound for promoting angiogenesis (the development of new blood vessels) for treatment of vascular related indications. To date, MTX61 has been shown to generate fully functional de novo microvasculature in ischemic muscles. Following intramuscular or subcutaneous injection, MTX61 forms a local, nanofibrous, proangiogenic hydrogel matrix that initiates a biological cascade of controlled angiogenesis, physically supporting and stabilizing new blood-vessel formation.
A significant advantage of Matrx’s MTX61 over previously employed protein, gene and cellular approaches to the treatment of vascular disease is derived from the specific control nanofiber-forming peptide hydrogels exert on retention of the active component at the site of therapy, the capability of the hydrogel matrix to interact with local cells/tissue, and its eventual controlled degradation. SAPH™ – MDPs are comprised of naturally occurring amino acids, are biologically compatible, and non-toxic.
Intellectual Property: Matrx holds an exclusive, worldwide licensed patent on Multidomain Peptides for Promoting Angiogenesis – U.S. Patent 9,526,762; Issue date 12/27/2016.
Targeted indications for MTX61 include:
- Intermittent claudication (IC) & Critical Limb Ischemia (CLI)
- Skin grafts for treating severe burns
- Regenerative endodontics
- Diabetic foot ulcers
- Plastic/reconstructive surgery
- Tissue regeneration